American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 27, 2025

– May 30, 2025

Scottsdale, Arizona

Oral, Once-Daily LB-102: Recent Positive Results From a Phase 2 Study in Patients With Acute Schizophrenia

View all events

LEAD. LIVE. BOLDLY., LB, and associated logos are trademarks or registered trademarks of LB Pharmaceuticals Inc.
© 2026 LB Pharmaceuticals. All Rights Reserved.

View our Privacy Policy

We exist to boldly advance treatments that healthcare providers can readily use and patients can trust, with the goal of alleviating the burden of difficult-to-treat brain disorders for individuals, families, and society.

About Us

Our Commitment
Our Leadership
Contact Us

Pipeline & Innovation

LB-102 Overview
Our Pipeline
Our Clinical Trials
Scientific Resources

Patient Impact

Therapeutic Areas

Life at LB

Our Culture
Our Benefits
Our Careers

Investors & News

Overview
News
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
Investor FAQs

Scroll to Top

Secret Link